InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (5 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
5
T+90 hit rate
0%
T+90 mean return
-38.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Hagan Joseph P, Chairman & CEO. Officer active across 4 companies, notably Regulus Therapeutics Inc.. Cumulatively, 15 reports have been logged. Breakdown: 3 buys · 5 sells. Total volume traded: €257k. Activity tracked since 17 May 2021. The latest transaction was filed on 30 January 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations15 total
50,000 shares@ US$1.08529.6% of flowCommon StockSEC:0000950170-25-011853:0
Ideal exit: 27 Oct 2025 (T+270)
115,290 shares@ US$1.263226.2% of flowCommon StockSEC:0000950170-25-005883:0
218,750 shares@ US$1.3653.1% of flowCommon StockSEC:0000950170-25-004274:0
14,580 shares@ US$1.19062.9% of flowCommon StockSEC:0001209191-24-001873:0
30,000 shares0Common StockSEC:0001209191-24-001778:0
8,733 sharesCommon StockSEC:0001600620-23-000021:0
272 shares@ US$10.580.7% of flowCommon StockSEC:0001600620-23-000021:1
100,000 shares@ US$0.215243.1% of flowCommon StockSEC:0001209191-22-005061:0
Ideal exit: 23 Oct 2022 (T+270)
100,000 shares@ US$0.215286.1% of flowCommon StockSEC:0001209191-22-005061
Ideal exit: 23 Oct 2022 (T+270)
40,000 shares@ US$5.08100.0% of flowCommon StockSEC:0001628280-22-000182
40,000 shares@ US$5.080.0085% mcap50.0% of flowCommon StockSEC:0001628280-22-000182:0
15,000 shares0Common StockSEC:0001567619-21-012083:0
15,000 shares0Common StockSEC:0001567619-21-012083
4,186 shares@ US$0.896.9% of flowCommon StockSEC:0001209191-21-033297
4,186 shares@ US$0.896.9% of flowCommon StockSEC:0001209191-21-033297:0
15 of 15 declarations
About Hagan Joseph P
Joseph P. Hagan serves as President & CEO and Board Member at Regulus Therapeutics Inc. and Zosano Pharma Corp. In this role, he oversees the operations and strategy of both companies. His expertise in the biopharmaceutical sector allows him to contribute to innovation and growth.
